Gene info: ID 56301

Gene: SLC7A10

GENE ID: 56301

Synonyms: ASC1|HASC-1|asc-1

Description: solute carrier family 7 member 10

Gene type: protein-coding

Location: 19q13.11

dbXrefs: Ensembl:ENSG00000130876 MIM:607959 Vega:OTTHUMG00000180344 UniprotKB:Q9NS82

RefSeq: NC_000019.10

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 1

Sherlock p-value : 1.004e-1 (AD) 6.250e-1 (ND) (Frontal_Cortex)

Pascal p-value : 8.577e-1 (AD) 6.429e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
GRIN2C	0.892
SFXN5	0.88
GPR37L1	0.876
SLC13A5	0.863
BMP7	0.853
MLC1	0.85
FGFR3	0.848
PYGM	0.842
GPR143	0.84
OLFM2	0.839

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
SYNPO2	-0.439
PLA2G4A	-0.421
MARCH1	-0.421
FGF10	-0.418
SOGA3	-0.417
TPH2	-0.415
CCDC68	-0.413
ARHGEF28	-0.402
ITGBL1	-0.401
SH3BP5	-0.4

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
D000447	Aldehydes	Aldehydes results in increased expression of SLC7A10 mRNA	25014914
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of SLC7A10 mRNA	16483693
D001280	Atrazine	Atrazine results in increased expression of SLC7A10 mRNA	22378314
C006780	bisphenol A	bisphenol A affects the expression of SLC7A10 mRNA	21786754
C018475	butyraldehyde	butyraldehyde results in increased expression of SLC7A10 mRNA	26079696
D002509	Cephaloridine	Cephaloridine results in increased expression of SLC7A10 mRNA	18500788
D002737	Chloroprene	Chloroprene results in decreased expression of SLC7A10 mRNA	23125180
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of SLC7A10 mRNA	19549813
D003471	Cuprizone	Cuprizone results in decreased expression of SLC7A10 mRNA	26577399\|2752363
C014347	decitabine	decitabine affects the expression of SLC7A10 mRNA	23300844
D003907	Dexamethasone	[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of SLC7A10 mRNA	29288687
D003907	Dexamethasone	[rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of SLC7A10 mRNA	29288687
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of SLC7A10 mRNA	21266533
D002945	Cisplatin	Cisplatin affects the expression of SLC7A10 mRNA	23300844
C000944	dicrotophos	dicrotophos results in increased expression of SLC7A10 mRNA	28302478
D004041	Dietary Fats	Dietary Fats results in decreased expression of SLC7A10 mRNA	18042831
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of SLC7A10 mRNA	28412506
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of SLC7A10 mRNA	25242112
C118739	entinostat	entinostat results in increased expression of SLC7A10 mRNA	26272509\|2718838
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
D005839	Gentamicins	Gentamicins results in decreased expression of SLC7A10 mRNA	22061828
D017313	Fenretinide	Fenretinide results in decreased expression of SLC7A10 mRNA	28973697
D015056	1-Methyl-3-isobutylxanthine	[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of SLC7A10 mRNA	29288687
D015056	1-Methyl-3-isobutylxanthine	[rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of SLC7A10 mRNA	29288687
D007649	Ketamine	Ketamine results in increased expression of SLC7A10 mRNA	20080153
C008261	lead acetate	lead acetate results in increased expression of SLC7A10 protein	25242007
C432503	licarin A	[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of SLC7A10 mRNA	29288687
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of SLC7A10 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of SLC7A10 mRNA"	25554681
D000073878	Palm Oil	Palm Oil results in decreased expression of SLC7A10 mRNA	18042831
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
C496932	panobinostat	panobinostat results in increased expression of SLC7A10 mRNA	26272509
C046012	pentanal	pentanal results in increased expression of SLC7A10 mRNA	26079696
D010705	Phosgene	Phosgene affects the expression of SLC7A10 mRNA	16300373
C005556	propionaldehyde	propionaldehyde results in increased expression of SLC7A10 mRNA	26079696
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of SLC7A10 mRNA	24780913
C089730	rosiglitazone	[rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of SLC7A10 mRNA	29288687
C009250	sevoflurane	sevoflurane affects the expression of SLC7A10 mRNA	15967596
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SLC7A10 mRNA	17942748
C009495	titanium dioxide	titanium dioxide results in decreased expression of SLC7A10 mRNA	23557971\|2776080
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of SLC7A10 mRNA	20133372
C012589	trichostatin A	trichostatin A results in increased expression of SLC7A10 mRNA	24935251
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of SLC7A10 mRNA	19042947
C057693	troglitazone	troglitazone results in increased expression of SLC7A10 mRNA	28973697
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of SLC7A10 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of SLC7A10 mRNA	19101580\|2317975
D015215	Zidovudine	Zidovudine results in decreased expression of SLC7A10 mRNA	24292225
D015215	Zidovudine	Zidovudine results in increased expression of SLC7A10 mRNA	24292225

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0015175	neutral amino acid transmembrane transporter activity	-	IBA	21873635
GO:0015175	neutral amino acid transmembrane transporter activity	-	IDA	10863037
GO:0015179	L-amino acid transmembrane transporter activity	-	IBA	21873635
GO:0015194	L-serine transmembrane transporter activity	-	TAS	10863037

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003333	amino acid transmembrane transport	-	IBA	21873635
GO:0006865	amino acid transport	-	TAS	10734121
GO:0015804	neutral amino acid transport	-	IBA	21873635
GO:0015804	neutral amino acid transport	-	IDA	10863037
GO:0015825	L-serine transport	-	IEA	-
GO:0042941	D-alanine transport	-	IBA	21873635
GO:0042942	D-serine transport	-	IBA	21873635
GO:0050900	leukocyte migration	-	TAS	-
GO:0055085	transmembrane transport	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	NAS	10863037
GO:0016020	membrane	-	TAS	10734121

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-202733	Cell surface interactions at the vascular wall	TAS
R-HSA-210991	Basigin interactions	TAS
R-HSA-352230	Amino acid transport across the plasma membrane	TAS
R-HSA-382551	Transport of small molecules	TAS
R-HSA-425393	Transport of inorganic cations/anions and amino acids/oligopeptides	TAS
R-HSA-425407	SLC-mediated transmembrane transport	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
24046282	Analyses of synovial tissues from arthritic and protected congenic rat strains reveal a new core set of genes associated with disease severity. (2013 Nov 15)	Brenner M	Physiol Genomics